SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yongmei Su, Deshun Sun, Optimal control of anti-HBV treatment based on combination of Traditional Chinese Medicine and Western Medicine, Biomedical Signal Processing and Control, 2015, 15, 41

    CrossRef

  2. 2
    D. Bertacchi, F. Zucca, S. Foresti, D. Mangioni, A. Gori, Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach, Mathematical Medicine and Biology, 2014,

    CrossRef

  3. 3
    Nancy W. Y. Leung, Eva Herrmann, George K. K. Lau, Henry L. Y. Chan, Tokutei M. K. So, Stefan Zeuzem, Yu Dong, Aldo Trylesinski, Nikolai V. Naoumov, Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B, Infectious Diseases and Therapy, 2014, 3, 2, 191

    CrossRef

  4. 4
    Mansour Sheikhan, S. Amir Ghoreishi, Antiviral therapy using a fuzzy controller optimized by modified evolutionary algorithms: a comparative study, Neural Computing and Applications, 2013, 23, 6, 1801

    CrossRef

  5. 5
    P. Tchinda Mouofo, J.J. Tewa, B. Mewoli, S. Bowong, Optimal control of a delayed system subject to mixed control-state constraints with application to a within-host model of hepatitis virus B, Annual Reviews in Control, 2013, 37, 2, 246

    CrossRef

  6. 6
    Jun Nakabayashi, Akira Sasaki, A mathematical model of the intracellular replication and within host evolution of hepatitis type B virus: Understanding the long time course of chronic hepatitis, Journal of Theoretical Biology, 2011, 269, 1, 318

    CrossRef

  7. 7
    Kaifa Wang, Wenting Tan, Yingzi Tang, Guohong Deng, Numerical Diagnoses of Superinfection in Chronic Hepatitis B Viral Dynamics, Intervirology, 2011, 54, 6, 349

    CrossRef

  8. 8
    George KK Lau, Nancy Leung, Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study, The Korean Journal of Hepatology, 2010, 16, 3, 315

    CrossRef

  9. 9
    Kaifa Wang, Aijun Fan, Angela Torres, Global properties of an improved hepatitis B virus model, Nonlinear Analysis: Real World Applications, 2010, 11, 4, 3131

    CrossRef

  10. 10
    Redouane Qesmi, Jun Wu, Jianhong Wu, Jane M. Heffernan, Influence of backward bifurcation in a model of hepatitis B and C viruses, Mathematical Biosciences, 2010, 224, 2, 118

    CrossRef

  11. 11
    Jin Yang, Ting Cai, Guo-Qiang Lou, Anti-hepatitis B virus treatment guided by long-term virus kinetics stepwise tracing, Journal of Gastroenterology and Hepatology, 2009, 24, 6
  12. 12
    Nancy Leung, Cheng-Yuan Peng, Hie-Won Hann, Jose Sollano, Judy Lao-Tan, Chao-Wei Hsu, Laurentius Lesmana, Man-Fung Yuen, Lennox Jeffers, Morris Sherman, Albert Min, Kimberly Mencarini, Ulysses Diva, Anne Cross, Richard Wilber, Juan Lopez-Talavera, Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir, Hepatology, 2009, 49, 1
  13. 13
    J. L. Starkey, E. F. Chiari, H. C. Isom, Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro, Journal of General Virology, 2009, 90, 1, 115

    CrossRef

  14. 14
    Harel Dahari, Emi Shudo, Ruy M. Ribeiro, Alan S. Perelson, Modeling complex decay profiles of hepatitis B virus during antiviral therapy, Hepatology, 2009, 49, 1
  15. 15
    Sharon R. Lewin, Ruy M. Ribeiro, Anchalee Avihingsanon, Scott Bowden, Gail Matthews, Pip Marks, Stephen A. Locarnini, Kiat Ruxrungtham, Alan S. Perelson, Gregory J. Dore, Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1–hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy, Hepatology, 2009, 49, 4
  16. 16
    Chee-Kin Hui, Hai-Ying Zhang, Scott Bowden, Stephen Locarnini, John M. Luk, Kar-Wai Leung, Yui-Hung Yueng, April Wong, Frank Rousseau, Kwok-Yung Yuen, Nikolai N. Naoumov, George K.K. Lau, 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B, Journal of Hepatology, 2008, 48, 5, 714

    CrossRef

  17. 17
    Vana Sypsa, Angelos Hatzakis, Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials, Statistics in Medicine, 2008, 27, 30
  18. 18
    Manoj Kumar, Shiv K Sarin, Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection, Expert Review of Gastroenterology & Hepatology, 2008, 2, 4, 465

    CrossRef

  19. 19
    M. KUMAR, S. K. SARIN, Systematic review: combination therapies for treatment-naïve chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2008, 27, 12
  20. 20
    T. Asselah, O. Lada, N. Boyer, M. Martinot, P. Marcellin, Traitement de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2008, 32, 8-9, 749

    CrossRef

  21. 21
    George Z. Panos, Konstantinos M. Lampropoulos, Anna G. Angelousi, Gerasimos G. Charatsis, Matthew E. Falagas, Lamivudine and Famciclovir Treatment in HIV Patients With Acute Hepatitis B Virus Infection and Hepatitis B Reactivation, Journal of Clinical Gastroenterology, 2007, 41, 2, 222

    CrossRef

  22. 22
    Stanca M. Ciupe, Ruy M. Ribeiro, Patrick W. Nelson, Alan S. Perelson, Modeling the mechanisms of acute hepatitis B virus infection, Journal of Theoretical Biology, 2007, 247, 1, 23

    CrossRef

  23. 23
    Thea Thomas, Graham Foster, Nanomedicines in the treatment of chronic hepatitis C ? focus on pegylated interferon alpha-2a, International Journal of Nanomedicine, 2007, 2, 1, 19

    CrossRef

  24. 24
    Xuan Xiao, Shi-Huang Shao, Kuo-Chen Chou, A probability cellular automaton model for hepatitis B viral infections, Biochemical and Biophysical Research Communications, 2006, 342, 2, 605

    CrossRef

  25. 25
    James S. Park, Neeraj Saraf, Douglas T. Dieterich, HBV plus HCV, HCV plus HIV, HBV plus HIV, Current Gastroenterology Reports, 2006, 8, 1, 67

    CrossRef

  26. 26
    F. Blaine Hollinger, Daryl T.-Y. Lau, Hepatitis B: The Pathway to Recovery Through Treatment, Gastroenterology Clinics of North America, 2006, 35, 2, 425

    CrossRef

  27. 27
    F. Blaine Hollinger, Daryl T.-Y. Lau, Hepatitis B: The Pathway to Recovery Through Treatment, Gastroenterology Clinics of North America, 2006, 35, 4, 895

    CrossRef

  28. 28
    Martijn J. ter Borg, Monika van Zonneveld, Stefan Zeuzem, Hakan Senturk, Ulus S. Akarca, Christopher Simon, Bettina E. Hansen, Bart L. Haagmans, Robert A. de Man, Solko W. Schalm, Harry L.A. Janssen, Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response, Hepatology, 2006, 44, 3
  29. 29
    Vassiliki-Anastasia Sypsa, Konstantinos Mimidis, Nicholas C. Tassopoulos, Dimitrios Chrysagis, Themistoklis Vassiliadis, Antonios Moulakakis, Maria Raptopoulou, Caterina Haida, Angelos Hatzakis, A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative, Hepatology, 2005, 42, 1
  30. 30
    Chee-kin Hui, Albert Lie, Wing-yan Au, Shing-yan Ma, Yu-Hung Leung, Hai-ying Zhang, Jian Sun, Winnie W.W. Cheung, Chor-sang Chim, Yok-lam Kwong, Raymond Liang, George K.K. Lau, Effectiveness of Prophylactic Anti-HBV Therapy in Allogeneic Hematopoietic Stem Cell Transplantation with HBsAg Positive Donors, American Journal of Transplantation, 2005, 5, 6
  31. 31
    Avidan U. Neumann, Hepatitis B viral kinetics: A dynamic puzzle still to be resolved, Hepatology, 2005, 42, 2
  32. 32
    Karine Lacombe, Joël Gozlan, Pierre-Yves Boelle, Lawrence Serfaty, Fabien Zoulim, Alain-Jacques Valleron, Pierre-Marie Girard, Long-term hepatitis B virus dynamics in HIV–hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate, AIDS, 2005, 19, 9, 907

    CrossRef

  33. 33
    Hai-Ying Zhang, Amin A. Nanji, John M. Luk, Xiao-Ru Huang, Chung-Mau Lo, Yong Xiong Chen, Siu-Tsan Yuen, Hui Y. Lan, George K. K. Lau, Macrophage migration inhibitory factor expression correlates with inflammatory changes in human chronic hepatitis B infection, Liver International, 2005, 25, 3
  34. 34
    Mark Sulkowski, Teresa Wright, Stephen Rossi, Sanjeev Arora, Matthew Lamb, Ka Wang, Jean-Michel Gries, Sreeni Yalamanchili, Peginterferon Alfa-2a Does Not Alter the Pharmacokinetics of Methadone in Patients with Chronic Hepatitis C Undergoing Methadone Maintenance Therapy, Clinical Pharmacology & Therapeutics, 2005, 77, 3
  35. 35
    Tamer Sanlidag, Sinem Akcali, Beril Ozbakkaloglu, Serum hepatitis B DNA: stability in relation to multiple freeze–thaw procedures, Journal of Virological Methods, 2005, 123, 1, 49

    CrossRef

  36. 36
    Ulrike Mihm, Barbara Christine Gärtner, Dominik Faust, Wolf Peter Hofmann, Christoph Sarrazin, Stefan Zeuzem, Eva Herrmann, Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir–lamivudine combination therapy, Journal of Hepatology, 2005, 43, 2, 217

    CrossRef

  37. 37
    Patrick Marcellin, Herve Mommeja-Marin, Stephen L. Sacks, George K. K. Lau, Daniel Sereni, Jean-Pierre Bronowicki, Brian Conway, Christian Trepo, M. Robert Blum, Byung Chul Yoo, Elsa Mondou, Jeff Sorbel, Andrea Snow, Franck Rousseau, Hyo-Suk Lee, A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B, Hepatology, 2004, 40, 1
  38. 38
    Daryl T.-Y. Lau, Fernando E. Membreno, Antiviral therapy for treatment-naı̈ve hepatitis B virus patients, Gastroenterology Clinics of North America, 2004, 33, 3, 581

    CrossRef

  39. 39
    Hong Shen, Mazen Alsatie, George Eckert, Naga Chalasani, Lawrence Lumeng, Paul Y. Kwo, Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection, Clinical Gastroenterology and Hepatology, 2004, 2, 4, 330

    CrossRef

  40. 40
    Stephanos J Hadziyannis, George V Papatheodoridis, Emerging treatments in chronic hepatitis B, Expert Opinion on Emerging Drugs, 2004, 9, 2, 207

    CrossRef

  41. 41
    Nilesh B Shukla, Michael A Poles, Hepatitis B virus infection: co-infection with hepatitis C virus, hepatitis D virus, and human immunodeficiency virus, Clinics in Liver Disease, 2004, 8, 2, 445

    CrossRef

  42. 42
    Chee-kin Hui, Hai-ying Zhang, George K.K. Lau, Management of chronic hepatitis B in treatment-experienced patients, Gastroenterology Clinics of North America, 2004, 33, 3, 601

    CrossRef

  43. 43
    H. M. Younger, A. J. Bathgate, P. C. Hayes, Review article: nucleoside analogues for the treatment of chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2004, 20, 11-12
  44. 44
    W. Jessner, R. Stauber, F. Hackl, C. Datz, T. Watkins-Riedel, H. Hofer, A. Gangl, H. Kessler, P. Ferenci, Early viral kinetics on treatment with pegylated interferon-α-2a in chronic hepatitis C virus genotype 1 infection, Journal of Viral Hepatitis, 2003, 10, 1
  45. 45
    Luis S. Marsano, Hepatitis, Primary Care: Clinics in Office Practice, 2003, 30, 1, 81

    CrossRef

  46. 46
    Shing-yan Ma, George K.K. Lau, Vincent C.C. Cheng, Raymond Liang, Hepatitis B Reactivation in Patients Positive for Hepatitis B Surface Antigen Undergoing Autologous Hematopoietic Cell Transplantation, Leukemia & Lymphoma, 2003, 44, 8, 1281

    CrossRef

  47. 47
    Jean-Michel Pawlotsky, Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics, Journal of Hepatology, 2003, 39, 31

    CrossRef

  48. 48
    Fabien Zoulim, Hepatitis B virus resistance to antivirals: clinical implications and management, Journal of Hepatology, 2003, 39, 133

    CrossRef

  49. 49
    Robert P. Perrillo, Hepatitis B: Treatment strategies for currently available drugs, Current Hepatitis Reports, 2003, 2, 2, 63

    CrossRef

  50. 50
    Norio Akuta, Akihito Tsubota, Fumitaka Suzuki, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis – an open-cohort study, Journal of Hepatology, 2003, 38, 1, 91

    CrossRef

  51. 51
    Murat Saruc, Nuri Ozden, Nurten Turkel, Semin Ayhan, Lynette M. Hock, Isil Tuzcuoglu, Hakan Yuceyar, Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B, Journal of Pharmaceutical Sciences, 2003, 92, 7
  52. 52
    Hari S Conjeevaram, Anna Suk-Fong Lok, Management of chronic hepatitis B, Journal of Hepatology, 2003, 38, 90

    CrossRef

  53. 53
    Carlos Briones, Esteban Domingo, Carmen Molina-Parı́s, Memory in Retroviral Quasispecies: Experimental Evidence and Theoretical Model for Human Immunodeficiency Virus, Journal of Molecular Biology, 2003, 331, 1, 213

    CrossRef

  54. 54
    Andy S Yu, Emmet B Keeffe, Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period, Clinics in Liver Disease, 2003, 7, 3, 551

    CrossRef

  55. 55
    Stephanos J Hadziyannis, George V Papatheodoridis, Peginterferon-α2a(40 kDa) for chronic hepatitis C, Expert Opinion on Pharmacotherapy, 2003, 4, 4, 541

    CrossRef

  56. 56
    Costica Aloman, Jack R. Wands, Resistance of HBV to adefovir dipivoxil: A case for combination antiviral therapy?, Hepatology, 2003, 38, 6
  57. 57
    Ruth Chin, Stephen Locarnini, Treatment of chronic hepatitis B: current challenges and future directions, Reviews in Medical Virology, 2003, 13, 4
  58. 58
    Angeline Bartholomeusz, Phillip Furman, Stephen Locarnini, Frontiers in Viral Hepatitis, 2003,

    CrossRef

  59. 59
    Fabien Zoulim, A Preliminary Benefit-Risk Assessment of Lamivudine for the Treatment of Chronic Hepatitis B Virus Infection, Drug Safety, 2002, 25, 7, 497

    CrossRef

  60. 60
    Ke Cheng XU, Shao Bai LI, Shao Ji WENG, Chun LEI, Ping YE, Combined lamivudine and famciclovir therapy for patients with chronic hepatitis B, Chinese Journal of Digestive Diseases, 2002, 3, 2
  61. 61
    Ruy M. Ribeiro, Arthur Lo, Alan S. Perelson, Dynamics of hepatitis B virus infection, Microbes and Infection, 2002, 4, 8, 829

    CrossRef

  62. 62
    RAJKUMAR C GUPTAN, VARSHA THAKUR, SEYED N KAZIM, SHIV K SARIN, Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients, Journal of Gastroenterology and Hepatology, 2002, 17, 7
  63. 63
    William E Delaney IV, Angeline Bartholomeusz, Stephen A Locarnini, Evolving therapies for the treatment of chronic hepatitis B virus infection, Expert Opinion on Investigational Drugs, 2002, 11, 2, 169

    CrossRef

  64. 64
    Sharon Lewin, Tomos Walters, Stephen Locarnini, Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies, Antiviral Research, 2002, 55, 3, 381

    CrossRef

  65. 65
    Ruy M Ribeiro, Alan S Perelson, Hepatitis B virus viral dynamics: effects of drug dose and baseline alanine aminotransferase, Journal of Hepatology, 2002, 37, 2, 277

    CrossRef

  66. 66
    Robert P. Perrillo, How will we use the new antiviral agents for hepatitis B?, Current Gastroenterology Reports, 2002, 4, 1, 63

    CrossRef

  67. 67
    CHUTIMA PRAMOOLSINSUP, Management of viral hepatitis B, Journal of Gastroenterology and Hepatology, 2002, 17,
  68. 68
    Alan S. Perelson, MODELLING VIRAL AND IMMUNE SYSTEM DYNAMICS, Nature Reviews Immunology, 2002, 2, 1, 28

    CrossRef

  69. 69
    G. K. K. Lau, A. Nanji, J. Hou, D. Y. T. Fong, W.-S. Au, S.-T. Yuen, M. Lin, H.-F. Kung, S.-K. Lam, Thymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase, Journal of Viral Hepatitis, 2002, 9, 4
  70. 70
    Markus Cornberg, Heiner Wedemeyer, Michael P. Manns, Treatment of chronic hepatitis C with PEGylated interferon and ribavirin, Current Gastroenterology Reports, 2002, 4, 1, 23

    CrossRef

  71. 71
    Leonieke M. M. Wolters, Bettina E. Hansen, Hubert G. M. Niesters, Robert A. de Man, Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine–famciclovir or lamivudine–ganciclovir, European Journal of Gastroenterology & Hepatology, 2002, 14, 9, 1007

    CrossRef

  72. 72
    Suzane Kioko Ono-Nita, Naoya Kato, Yasushi Shiratori, Masao Omata, Current options for the therapy of chronic hepatitis B infection, Current Infectious Disease Reports, 2001, 3, 2, 137

    CrossRef

  73. 73
    Mark V Galan, Stuart C Gordon, Douglas Boyce, Current pharmacotherapy for hepatitis B infection, Expert Opinion on Pharmacotherapy, 2001, 2, 8, 1289

    CrossRef

  74. 74
    G. V. Papatheodoridis, S. J. Hadziyannis, Diagnosis and management of pre-core mutant chronic hepatitis B, Journal of Viral Hepatitis, 2001, 8, 5
  75. 75
    Vicente Carreño, Miguel A Rico, Margarita Pardo, Juan Antonio Quiroga, Extended follow-up of anti-HBe-positive patients with chronic hepatitis B retreated with ribavirin and interferon-α, Antiviral Research, 2001, 52, 2, 147

    CrossRef

  76. 76
    George K.K. Lau, HEPATITIS B INFECTION IN CHINA, Clinics in Liver Disease, 2001, 5, 2, 361

    CrossRef

  77. 77
    Luo Xunrong, Au Wing Yan, Raymond Liang, George K. K. Lau, Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy — pathogenesis and management, Reviews in Medical Virology, 2001, 11, 5
  78. 78
    Karl P Fischer, Klaus S Gutfreund, D.Lorne Tyrrell, Lamivudine resistance in hepatitis B: mechanisms and clinical implications, Drug Resistance Updates, 2001, 4, 2, 118

    CrossRef

  79. 79
    Anna S. Lok, E.Jenny Heathcote, Jay H. Hoofnagle, Management of hepatitis B: 2000—Summary of a workshop, Gastroenterology, 2001, 120, 7, 1828

    CrossRef

  80. 80
    B Werle, F Zoulim, Nouveaux traitements de l'hépatite B et techniques d'étude de la résistance virale, Immuno-analyse & Biologie Spécialisée, 2001, 16, 3, 158

    CrossRef

  81. 81
    Leonieke M. M. Wolters, Hubert G. M. Niesters, Robert A. de Man, Nucleoside analogues for chronic hepatitis B, European Journal of Gastroenterology & Hepatology, 2001, 13, 12, 1499

    CrossRef

  82. 82
    Mindie H. Nguyen, Teresa L. Wright, Therapeutic advances in the management of hepatitis B and hepatitis C, Current Opinion in Infectious Diseases, 2001, 14, 5, 593

    CrossRef

  83. 83
    Norah A. Terrault, Combined Interferon and Lamivudine Therapy: Is This The Treatment of Choice for Patients With Chronic Hepatitis B Virus Infection?, Hepatology, 2000, 32, 3
  84. 84
    &NA;, Famciclovir-based regimens effective ..., Inpharma Weekly, 2000, &NA;, 1255, 20

    CrossRef